PARIS: EssilorLuxottica, a leading global eyewear company, has acquired Cellview Imaging Inc., a Canadian start-up specializing in innovative retinal diagnostic imaging, as part of its ongoing commitment to elevate industry standards and improve the quality of vision care.
The acquisition aims to expand EssilorLuxottica’s portfolio of ophthalmic instruments and solutions, marking a significant step in its journey into the med-tech space.
Cellview, based in Toronto, designs and manufactures high-performance diagnostic imaging instruments, leveraging its robust internal R&D expertise. Currently distributed in North America, Cellview’s solutions enable eyecare practitioners to diagnose retinal pathologies using an ultra-widefield retinal camera that captures significantly larger images compared to most existing technologies.
The company’s product offerings, which are FDA and CE approved, target a broad market base, from eyecare practices in retail locations to ophthalmology clinics, and are set to be distributed in different geographies, starting with Europe.
“We are happy to welcome Cellview’s team to EssilorLuxottica and to work together to accelerate our strategy in vision health,” said Francesco Milleri, Chairman and CEO, and Paul du Saillant, Deputy CEO at EssilorLuxottica.
“By integrating another pioneering company with strong expertise in R&D and world-class imaging solutions, we will provide a comprehensive portfolio of innovative technologies to the ophthalmic care community to better address the growing need for vision health and the early diagnosis of retinal pathologies. While our products and services remain accessible to all industry players – as a pillar of EssilorLuxottica’s open business model – we continue to elevate market standards, in full alignment with our journey into the med-tech space.”